Progressive Keratoconus or Ectasia Treatment Plan

NCT01384773 | Unknown

• 1 other identifier: AAAF0594
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Keratoconus and pellucid marginal degenerations are genetically based ocular conditions and post surgical ectasia is an iatrogenic condition. These diseases are characterized by weakening of the front part of the eye that causes thinning and distortion. This distortion results in unevenness of the cornea and produces progressive near-sightedness and irregularity, which causes loss of vision when using eyeglasses. When eyeglasses fail to give enough vision, the the investigators use rigid contact lenses to create an artificial front eye surface. This improves visual acuity in many patients although they eventually fail either because they cannot be tolerated or the surface irregularity has become so severe that they are rejected. At this stage there is usually thinning and loss of clarity of the eye. There has been no treatment for this other than corneal transplantation, a complex surgical procedure with a significant complication rate and a delay in visual recovery. The treatment the investigators wish to perform strengthens the front of the eye by a chemical reaction using light and riboflavin. This technique has been studied over a decade and is widely used throughout the world. The FDA approved multicenter American clinical study is being analyzed in anticipation of its submission to the FDA for PreMarket approval. Because this is a progressive condition, the investigators wish to be able to offer this on a limited basis to patients in need with vision loss. Any treatment that can delay or prevent corneal transplantation is of great benefit. The investigators believe the evidence is compelling that this treatment is the sole alternative to surgical transplantation.

Conditions

Keratoconus; Ectasia

Keywords

Keratoconus; Ectasia; UVA light; riboflavin; post-LASIK (laser in situ keratomileusis); pellucid marginal degeneration; irregular astigmatism

Interventions

Riboflavin Solution OTHER

This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.

Also known as: Medio-Cross Riboflavin 0.1% ophthalmic solution

UV-X Illumination System DEVICE

IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.

Also known as: IROC UV-X System

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects who have one or both eyes that meet all of the following criteria will be considered candidates for this treatment:
• For Keratoconus and Post Refractive Surgery Ectasia:
• years of age or older
• Having a diagnosis of keratoconus with one or more of the following changes over a period of 24 months or less.
• An increase of \> 1.00 D in the steepest keratometry value (or sim K)
• An increase of \> 1.00 D in regular astigmatism evaluated by subjective manifest refraction
• A myopic shift (decrease in the spherical equivalent) of \> 0.50 D on subjective manifest refraction
• Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.
• Presence of central or inferior steepening on the Pentacam map.
• Axial topography consistent with keratoconus
• Slit lamp findings associated with keratoconus must be documented:
• Fleischer ring
• Vogt striae
• Corneal thinning
• Corneal scarring

You may not qualify if:

• All subjects meeting any of the following criteria will be excluded from this treatment:
• No evidence of progression.
• Excessively thin corneas.
• Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:
• History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)
• Clinically significant corneal scarring in the proposed treatment zone
• A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.
• A known sensitivity to treatment medications
• Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.

Sponsors & Collaborators

• Stephen Trokel: lead

Study Sites (1)

Edward Harkness Eye Institute-Columbia University Medical Center

New York, New York, 10032, United States

Location

Related Publications (1)

• Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5. doi: 10.3928/1081597X-20080901-15.

  PMID: 18811118 BACKGROUND

MeSH Terms

Conditions

Keratoconus; Dilatation, Pathologic

Interventions

Ophthalmic Solutions

Condition Hierarchy (Ancestors)

Corneal Diseases; Eye Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pharmaceutical Solutions; Solutions; Pharmaceutical Preparations; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses; Specialty Uses of Chemicals

Study Officials

• Stephen L Trokel, MD

  Columbia University, Department of Ophthalmology, College of Physicians and Surgeons

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: expanded access
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of Clinical Ophthalmology

Study Record Dates

• First Submitted: June 27, 2011
• First Posted: June 29, 2011
• Last Updated: February 9, 2023

Record last verified: 2023-02

Locations

US (1)